The U.S. Food and Drug Administration (FDA) approved a supplemental application for Wegovy (semaglutide) on November 21, 2025. This approval, designated as NDA 215256 S-23, specifically relates to the efficacy of the drug, indicating a review and acceptance of additional data supporting its effectiveness.
Background
Wegovy is a brand name for semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist. It is approved for chronic weight management in adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity, such as hypertension, type 2 diabetes, or dyslipidemia. This supplemental approval for efficacy indicates that the FDA has reviewed and accepted additional data pertaining to the drug's effectiveness in its therapeutic applications.
What this means
This supplemental approval for Wegovy (semaglutide) signifies that the FDA has evaluated and accepted new information regarding the drug's efficacy. Such approvals can reflect a deeper understanding of the drug's mechanism of action, its long-term benefits, or its effectiveness in specific patient subgroups within its approved indications. For clinicians and patients, this reinforces the evidence base supporting Wegovy's use for its approved purposes, potentially leading to updated prescribing information or enhanced confidence in its therapeutic profile.
Source
This information was obtained from the U.S. Food and Drug Administration (FDA) through its official Drugs@FDA database. The supplemental application approval for Wegovy (semaglutide), identified as NDA 215256 S-23, was recorded on November 21, 2025, on accessdata.fda.gov.